On the other hand, the association of increased risk of ER-negative breast cancer with high OPG levels may be linked to OPG’s role as a decoy receptor for TRAIL, and therefore inhibiting TRAIL-induced apoptotic effects in neoplastic cells and enhancing the survival of ER-negative tumor cells [33,35]. The gene discussed is TNFRSF11B; the disease is neoplasm.